Search research articles
Contact Us
Filters
Showing results (1-10 of 317) with videos related to
Page
of 32
Sort By:
Future Microbiology
|
March 10, 2010
Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view
Kevin L Winthrop
Nature Clinical Practice. Rheumatology
|
November 1, 2006
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
Kevin L Winthrop
Nature Reviews. Rheumatology
|
March 3, 2017
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L Winthrop
Nature Reviews. Rheumatology
|
April 1, 2017
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L Winthrop
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 18, 2020
Who Needs a Corona?
Kevin L Winthrop
Rheumatic Diseases Clinics of North America
|
November 10, 2012
Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention
Kevin L Winthrop
Nature Reviews. Rheumatology
|
July 2, 2009
Preventing and treating biologic-associated opportunistic infections
Kevin L Winthrop, Tom Chiller
Infectious Disease Clinics of North America
|
May 24, 2020
Mycobacterial Infections Potentiated by Biologics
Cassandra Calabrese, Kevin L Winthrop
Annals of the Rheumatic Diseases
|
March 4, 2021
Rheumatology and COVID-19 at 1 year: facing the unknowns
Leonard Calabrese, Kevin L Winthrop
Nature Reviews. Rheumatology
|
June 2, 2017
Pharmacotherapy: Biosimilar switching - "To set a form upon desired change"
Jonathan Kay, Kevin L Winthrop
Page
of 32
Search research articles
Search
Showing results (1-10 of 317) with videos related to
Sort By:
Page
of 32
Future Microbiology
|
March 10, 2010
Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view
Kevin L Winthrop
Nature Clinical Practice. Rheumatology
|
November 1, 2006
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
Kevin L Winthrop
Nature Reviews. Rheumatology
|
March 3, 2017
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L Winthrop
Nature Reviews. Rheumatology
|
April 1, 2017
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L Winthrop
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 18, 2020
Who Needs a Corona?
Kevin L Winthrop
Rheumatic Diseases Clinics of North America
|
November 10, 2012
Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention
Kevin L Winthrop
Nature Reviews. Rheumatology
|
July 2, 2009
Preventing and treating biologic-associated opportunistic infections
Kevin L Winthrop, Tom Chiller
Infectious Disease Clinics of North America
|
May 24, 2020
Mycobacterial Infections Potentiated by Biologics
Cassandra Calabrese, Kevin L Winthrop
Annals of the Rheumatic Diseases
|
March 4, 2021
Rheumatology and COVID-19 at 1 year: facing the unknowns
Leonard Calabrese, Kevin L Winthrop
Nature Reviews. Rheumatology
|
June 2, 2017
Pharmacotherapy: Biosimilar switching - "To set a form upon desired change"
Jonathan Kay, Kevin L Winthrop
Page
of 32